Dr. Michael Cheng
Claim this profileDana Farber Cancer Institute
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
6 reported clinical trials
17 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Stage III
Stage IV
metastatic
2Lung Cancer
Stage III
Stage IV
Stage I
Affiliated Hospitals
Clinical Trials Michael Cheng is currently running
Sigvotatug Vedotin vs Docetaxel
for Lung Cancer
This trial is testing a new drug, sigvotatug vedotin, against a standard drug, docetaxel, in patients with advanced lung cancer. The goal is to see if the new drug works better and to understand its side effects. Docetaxel (Taxotere) is a well-established chemotherapy agent used in the treatment of advanced non-small cell lung cancer (NSCLC), often after failure of first-line treatments.
Recruiting2 awards Phase 35 criteria
ZEN003694 + Chemotherapy
for Cancer
This phase I/II trial tests the safety, side effects, and best dose of a new combination of drugs, ZEN003694, cisplatin, and etoposide in treating patients with NUT carcinoma (phase I), and identifies whether this combination therapy works to shrink tumor in these patients (phase II). Another purpose of this study is to see whether there are any changes in patient's tumor or blood characteristics (e.g. genes, molecules, etc.) due to combination therapy. ZEN003694 inhibits the production of certain growth-promoting proteins and may prevent proliferation of tumor cells that use those proteins for their growth. Chemotherapy drugs, such as etoposide and cisplatin, work by stopping or slowing the growth of cancer cells. Combination therapy with ZEN003694, etoposide and cisplatin may be effective in treating patients with NUT carcinoma.
Recruiting1 award Phase 1 & 2
More about Michael Cheng
Clinical Trial Related4 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Michael Cheng has experience with
- Pembrolizumab
- Carboplatin
- ZEN003694
- Cisplatin
- Etoposide
- Paclitaxel
Breakdown of trials Michael Cheng has run
Non-Small Cell Lung Cancer
Lung Cancer
Squamous Cell Carcinoma
Neuroendocrine Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Cheng specialize in?
Michael Cheng focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage III patients, or patients who are Stage IV.
Is Michael Cheng currently recruiting for clinical trials?
Yes, Michael Cheng is currently recruiting for 2 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Michael Cheng has studied deeply?
Yes, Michael Cheng has studied treatments such as Pembrolizumab, Carboplatin, ZEN003694.
What is the best way to schedule an appointment with Michael Cheng?
Apply for one of the trials that Michael Cheng is conducting.
What is the office address of Michael Cheng?
The office of Michael Cheng is located at: Dana Farber Cancer Institute, Boston, Massachusetts 02115 United States. This is the address for their practice at the Dana Farber Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.